Sage Journals: Discover world-class research

Abstract

Hepatitis B is a major global threat and over two billion people have been infected. The major impact is from the chronic form of the disease which is associated with cirrhosis, liver failure and hepatocellular carcinoma. An effective vaccination has been available for decades and it is important to understand which people to target in immunisation programmes. This requires knowledge of groups at high risk for contracting the virus and the current NHS strategy about who should be offered immunisation. A basic understanding of common presentations, risk factors, serological testing and immunisation for hepatitis B are keys to its successful management.

Get full access to this article

View all access options for this article.

References

Advisory Group on Hepatitis. (2009). Case-finding for hepatitis B and C virus infection in minority ethnic populations in the United Kingdom. Advisory Group on Hepatitis..

Allaby, M. (2009). Case-finding for hepatitis B and C virus infection in minority ethnic populations in the United Kingdom. Advisory group on hepatitis. Retrieved from www.screening.nhs.uk/policydb_download.php?doc=127.

British Association of Sexual Health and HIV. (2006). Sexually transmitted infections: UK national screening and testing guidelines. Retrieved from www.bashh.org/documents/59/59.pdf.

Centres for Disease Control and Prevention. (2012). Map of epidemic state of hepatitis B. Yellow book Chapter 3 (71) Hepatitis B. Retrieved from wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm.

Chang

T. T.

Gish

R. G.

de Man

Gadano

Sollano

Chao

Y. C.

Apelian

(2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 354: 1001–1010. doi: 10.1056/NEJMoa051285.

Department of Health. (2002). Getting ahead of the curve: a strategy for combating infectious disease (including other aspects of health protection). A report by the Chief Medical Officer. London. Retrieved from http://webarchive.nationalarchives.gov.uk/20130107105354/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4007697.

Department of Health (2007). Hepatitis B infected healthcare workers and antiviral therapy. Best practice guidance. Retrieved from http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_073133.pdf.

EASL (2012) Clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology 57: 167–185. Retrieved from www.easl.eu/assets/application/files/b73c0da3c52fa1d_file.pdf.

Goldstein

Zhou

Hadler

Bell

Mast

Margolis

(2005) A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 34: 1329–1339. doi: 10.1093/ije/dyi206.

10.

Hahné

Ramsay

Balogun

Edmunds

W. J.

Mortimer

(2004) Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: Implications for immunisation policy. Journal of Clinical Virology 29: 211–220. Retrieved from www.journalofclinicalvirology.com/article/S1386-6532(03)00276-2/abstract.

11.

Heptonstall, J. (1992). Communicable disease report – exposure to hepatitis B virus: Guidance on post exposure prophylaxis. PHLS Hepatitis Subcommittee, volume 2, review no. 9, 14 August 1992. Retrieved from http://webarchive.nationalarchives.gov.uk/+/http://www.hpa.org.uk/cdr/archives/CDRreview/1992/cdrr0992.pdf.

12.

Kwon

Lok

(2011) Hepatitis B therapy. Nature Reviews Gastroenterology & Hepatology 8: 275–284. doi: 10.1038/nrgastro.2011.33.

13.

Lau

G. K.

Piratvisuth

Luo

K. X.

Marcellin

Thongsawat

Cooksley

Pluck

(2005) Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New England Journal of Medicine 352: 2682–2695. doi: 10.1056/NEJMoa043470.

14.

Lavanchy

(2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11(2): 97–107. doi: 10.1046/j.1365-2893.2003.00487.x.

15.

Liaw

Y. F.

Tsai

S. L.

Sheen

I. S.

Chao

Yeh

C. T.

Hsieh

S. Y.

Chu

C. M.

(1998) Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. American Journal of Gastroenterology 93(3): 354–359. doi: 10.1016/S0002-9270(97)00104-4.

16.

Lok

A. S.

McMahon

B. J.

(2009) Chronic HBV infection: American Association for the Study of Liver (AASLD) guidelines for initiating therapy. Update. Hepatology 50(3): 661–662. doi: 10.1002/hep.23190.

17.

Marcellin

Chang

T. T.

Lim

S. G.

Tong

M. J.

Sievert

Shiffman

M. L.

Brosgart

C. L.

(2003) Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. New England Journal of Medicine 348: 808–816. doi: 10.1056/NEJM200303203481229.

18.

Marcellin

Heathcote

E. J.

Buti

Gane

de Man

R. A.

Krastev

Rousseau

(2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New England Journal of Medicine 359: 2442–2455. doi: 10.1056/NEJMoa0802878.

19.

Mast

E. E.

Weinbaum

C. M.

Fiore

A. E.

Alter

M. J.

Bell

B. P.

Finelli

Ward

J. W.

(2006) A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of adults. Centers for Disease Control and Prevention (CDC). Morbidity and Mortality Weekly Report. Recommendations and Reports 55(RR-16): 1–33. Retrieved from www.cdc.gov/MMWR/PREVIEW/mmwrhtml/rr5516a1.htm.

20.

McMahon

B. J.

Alward

W. L.

Hall

D. B.

Heyward

W. L.

Bender

T. R.

Francis

D. P.

Maynard

J. E.

(1985) Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. Journal of Infectious Diseases 151(4): 599–603. doi: 10.1093/infdis/151.4.599.

21.

NICE. (2006). Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Retrieved from www.guidance.nice.org.uk/ta96.

22.

RCGP. (2005). Guidance for hepatitis A and B vaccination of drug users in primary care and audit. Retrieved from www.smmgp.org.uk/download/guidance/guidance014.pdf.

23.

RCGP. Clinical example 3.08: Sexual health. Retrieved from www.rcgp.org.uk/gp-training-and-exams/∼/media/Files/GP-training-and-exams/Curriculum-2012/RCGP-Curriculum-3-08-Sexual-Health.ashx.

24.

RCGP. Clinical example 3.13: Digestive health. Retrieved from www.rcgp.org.uk/gp-training-and-exams/∼/media/Files/GP-training-and-exams/Curriculum-2012/RCGP-Curriculum-3-13-Digestive-Health.ashx.

25.

Strader

D. B.

(2002) Understudied populations with hepatitis C. Hepatology 36(S5): S226–S236. doi: 10.1053/jhep.2002.36991.

26.

Wang

Jiang

Liang

Xiao

H. J.

Xiang

Shi

J. F.

Bofetta

(2012) Attributable causes of cancer in China. Annals of Oncology 23(11): 2983–2989. doi: 10.1093/annonc/mds139.